(Q38167355)

English

Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs

scientific article published on 02 December 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

based on heuristic

inferred from title

Peer Carsten Tfelt-Hansen

1

object named as

Peer C Tfelt-Hansen

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

author name string

Thomas Pihl

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Anders Hougaard

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Dimos D Mitsikostas

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

2 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

375-385

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

The global burden of headache: a documentation of headache prevalence and disability worldwide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Indirect cost burden of migraine in the United States

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Cost of disorders of the brain in Europe

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

The discovery and development of the triptans, a major therapeutic breakthrough

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Over-the-counter triptans for migraine : what are the implications?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Taking the negative view of current migraine treatments: the unmet needs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

5-HT1F Receptor Agonists in Acute Migraine Treatment: A Hypothesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

What do patients with migraine want from acute migraine treatment?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Unpublished clinical trials with sumatriptan

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Coronary side-effect potential of current and prospective antimigraine drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Effect of migraine attacks on paracetamol absorption

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Clinical pharmacokinetics of intranasal sumatriptan.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Zelrix: a novel transdermal formulation of sumatriptan.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

A sumatriptan iontophoretic transdermal system for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

What do patients want from acute migraine treatment?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Breath actuated device improves delivery to target sites beyond the nasal valve

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Publication committees in clinical trials in headache

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Increasing the effect of triptans in migraine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.861817

21 January 2018

Identifiers

10.1517/13543784.2014.861817

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38167355&oldid=1745363501"